1887
Rapid communication Open Access
Like 0

Abstract

Three confirmed infections with the SARS-CoV-2 B.1.640 variant under monitoring were reported in Normandy, north-western France in late November 2021. Investigations led to the identification of two events linked to the same cluster. A total of 75 confirmed and probable B.1.640 cases were reported. All had completed the primary vaccination series. Sixty-two cases were older than 65 years. Fifty-six cases had symptoms and four were hospitalised. This investigation provides preliminary results concerning a variant with limited information currently available.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.6.2200078
2022-02-10
2022-12-01
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2022.27.6.2200078
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/6/eurosurv-27-6-2.html?itemId=/content/10.2807/1560-7917.ES.2022.27.6.2200078&mimeType=html&fmt=ahah

References

  1. Cov-Lineages. Lineage B.1.640. PANGO lineages: latest epidemiological lineages of SARS-CoV-2. [Accessed: 13 Jan 2022]. Available from: https://cov-lineages.org/lineage.html?lineage=B.1.640
  2. World Health Organization (WHO). Tracking SARS-CoV-2 variants. Geneva: WHO. [Accessed: 13 Jan 2022]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
  3. Protocols.io. nCoV-2019 sequencing protocol v3 (LoCost). Berkeley: protocils.io; 2020. Available from: https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye
  4. Nextclade. Clade assignment, mutation calling, and sequence quality checks. [Accessed: 20 Jan 2022]. Available from: https://clades.nextstrain.org
  5. Database EMERGEN. L'outil de dépôt du consortium EMERGEN. [The deposit tool of the EMERGEN consortium]. Saint-Maurice: Santé publique France. [Accessed: 20 Jan 2022]. French. Available from: https://emergen-db.france-bioinformatique.fr
  6. GISAID. Tracking of variants. [Accessed: 14 Jan 2022]. Available from: https://www.gisaid.org/hcov19-variants
  7. Sante Publique France. Analyse de risque sur les variants émergents du SARS-CoV-2 réalisée conjointement par Santé publique France et le CNR des virus des infections respiratoires. [Risk analysis on emerging variants of SARS-CoV-2 carried out jointly by Public Health France and the CNR for respiratory infection viruses]. 5 Jan 2022. Saint-Maurice: Sante publique France; 2022. French. Available from: https://www.santepubliquefrance.fr/media/files/01-maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/analyse-de-risque-des-variants-emergents-de-sars-cov-2-05-01-22
  8. Sante publique France. Coronavirus: circulation des variants du SARS-CoV-2. [Coronavirus: circulation of SARS-CoV-2 variants]. 28 Jan 2022. Saint-Maurice: Sante publique France; 2022. French. Available from: https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-circulation-des-variants-du-sars-cov-2
  9. Lee H, Han C, Jung J, Lee S. Analysis of superspreading potential from transmission clusters of COVID-19 in South Korea. Int J Environ Res Public Health. 2021;18(24):12893.  https://doi.org/10.3390/ijerph182412893  PMID: 34948504 
  10. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(31):1059-62.  https://doi.org/10.15585/mmwr.mm7031e2  PMID: 34351882 
  11. Botton J, Dray-Spira R, Baricault B, Drouin J, Bertrand M, Jabagi M-J, et al. Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines. Vaccine. 2022;40(3):414-7.  https://doi.org/10.1016/j.vaccine.2021.12.009  PMID: 34924220 
  12. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043-54.  https://doi.org/10.1001/jama.2021.19499  PMID: 34734975 
  13. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):e85.  https://doi.org/10.1056/NEJMoa2114228  PMID: 34706170 
  14. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.  https://doi.org/10.1056/NEJMoa2114583  PMID: 34614326 
  15. Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine. JAMA Intern Med. 2022;182(2):179-84.  https://doi.org/10.1001/jamainternmed.2021.7382  PMID: 34846533 
/content/10.2807/1560-7917.ES.2022.27.6.2200078
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error